The U.S. Idiopathic Thrombocytopenic Purpura Therapeutics Market to reach US$ 361.8 Million and Likely to Expand at a 4.8% Value CAGR over the Forecast Period.
The U.S. Idiopathic Thrombocytopenic Purpura Therapeutics Market to reach US$ 361.8 Million and Likely to Expand at a 4.8% Value CAGR over the Forecast Period.
Increasing Incidences Of Acute As Well As Prolonged Chronic Immune Thrombocytopenia Are Projected To Drive the Acceptance Of Therapeutics Treatment Globally During The Forecast Period.
Fact.MR, a Market Research and Competitive Intelligence Provider - As per a recent report published by Fact.MR, the global idiopathic thrombocytopenic purpura therapeutics market is poised to grow at a CAGR of 5.0% from 2022 to 2032. By the end of the said forecast period, the industry is likely to reach US$ 1.0 Billion. From 2015 to 2021, the market for idiopathic thrombocytopenic purpura therapeutics grew at a CAGR of 5.6%. As of 2022, the industry is likely to reach US$ 620.5 Million.
The potential commercialization of new products such as Avatrombopag by Eisai and IVIG3I 10% by Grifols, is one of the major key trends that is expected to fuel the growth of the Idiopathic Thrombocytopenic Purpura Therapeutics market during the forecast period. Avatrombopag has demonstrated positive clinical trial results and is expected to present patients with an alternative second line of treatment upon commercialization.
Want A Detailed Understanding of Idiopathic Thrombocytopenic Purpura Therapeutics Market? Request for a Sample Here
https://www.factmr.com/connectus/sample?flag=S&rep_id=7449
Increasing demand for combination therapies therapy is expected to fuel market growth. Clinical evidence suggests that combination therapies entail relatively lower side effects, are cost-effective, and display higher response rates in patients. Some major combination therapies include corticosteroids and IVIG, rituximab and dexamethasone, TPO-RA (eltrombopag), and dexamethasone. Splenectomy also plays an integral role in shaping the dynamics of the ITP therapeutics market. The procedure refers to the removal of the spleen and is aimed at reducing the amount of anti-platelet antibodies. Two therapeutic classes most affected by splenectomy are TPO-RA and anti-D.
Idiopathic Thrombocytopenic Purpura Therapeutics Market Revenue Key Trends
The potential commercialization of new products such as Avatrombopag by Eisai and IVIG3I 10% by Grifols, is one of the major key trends that is expected to fuel the growth of the Idiopathic Thrombocytopenic Purpura Therapeutics market during the forecast period. Avatrombopag has demonstrated positive clinical trial results and is expected to present patients with an alternative second line of treatment upon commercialization.
Increasing demand for combination therapies therapy is expected to fuel the growth of the Idiopathic Thrombocytopenic Purpura Therapeutics market. Clinical evidence suggests that combination therapies entail relatively lower side effects, are cost-effective, and display higher response rates in patients. Some major combination therapies include corticosteroids and IVIG, rituximab and dexamethasone, TPO-RA (eltrombopag), and dexamethasone.
Splenectomy also plays an integral role in shaping the dynamics of the ITP therapeutics market. The procedure refers to the removal of the spleen and is aimed at reducing the amount of anti-platelet antibodies. Two therapeutic classes most affected by splenectomy are TPO-RA and anti-D.
To gain in-depth insights on Idiopathic Thrombocytopenic Purpura Therapeutics Market Report, Request Methodology at
https://www.factmr.com/connectus/sample?flag=RM&rep_id=7449
Key Takeaways from Idiopathic Thrombocytopenic Purpura Therapeutics Market Study
- Global idiopathic thrombocytopenic purpura therapeutics market to generate a US$ 390.9 Million opportunity until 2032
- Corticosteroids to be top product type, flourishing at a 5.0% CAGR until 2032
- By distribution channel, retail pharmacies to be most preferred point of sale, expanding at a 5.1% CAGR
- U.S to emerge as the fastest growing idiopathic thrombocytopenic purpura therapeutics market, documenting a 4.8% CAGR
- China to be the second most opportunistic market, expected to be valued at US$ 72.7 Million in 2032
- Japan, U.K & South Korea to yield $ opportunities worth US$ 58.7 Million, US$ 41.4 Million, and US$ 36.6 Million respectively
Competitive Landscape
The global market for idiopathic thrombocytopenic purpura therapeutics is characterized by the presence of multiple vendors, aiming to offer extensive products to consumers. Additionally, key makers are focusing on developing devices supported by the implementation of stringent government regulations, and are offering solutions tailor-made to suit their business objectives. In addition, the vendors are likely to leverage upgradation and product differentiation to gain an edge over other competitors in the market.
- In February 2019, Paras Biopharmaceuticals Finland Oy announced the successful development of biologically active Romiplostim.
- In April 2018, U.S Food and Drug Administration (FDA) approved the therapeutic use of TAVALISSE developed by Rigel Pharmaceuticals, Inc. as the second line of treatment for ITP.
- In March 2018, Dova Pharmaceuticals, along with its wholly-owned subsidiary AkaRx, Inc. entered into a distribution and development rights agreement with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. For DOPTELET in China and Hong Kong.
Get Customization on this Report for Specific Research Solutions
https://www.factmr.com/connectus/sample?flag=RC&rep_id=7449
More Valuable Insights
The study, in its new offering, presents an unbiased analysis of the global Idiopathic Thrombocytopenic Purpura Therapeutics Market, presenting historical analysis from 2015 to 2021 and forecast statistics for the period of 2022-2032.
The study reveals essential insights on the basis of Product Type (corticosteroids, intravenous immunoglobulins, anti-d immunoglobulin, thrombopoietin receptor agonists (TPO-RA), and others), by distribution channel (drug store, retail pharmacies, and others) and treatment type (oral corticosteroids, and splenectomy) across five major regions (North America, Latin America, Asia Pacific, Europe and Middle East & Africa).
Fact.MR’s Domain Expertise in Healthcare Sector
Our healthcare consulting team guides organizations at each step of their business strategy by helping you understand how the latest influencers account for operational and strategic transformation in the healthcare sector. Our expertise in recognizing the challenges and trends impacting the global healthcare industry provides indispensable insights and support - encasing a strategic perspective that helps you identify critical issues and devise appropriate solutions.
Gene Therapy Market- The global gene therapy market is slated to acquire a valuation of US$ 1.85 Billion in 2022, up from US$ 1.55 Billion in 2021, representing a Y-o-Y increase of 19.3%. From 2022-2032, the market is poised to register a CAGR of 18.5%, reaching a valuation of US$ 10.1 Billion.
Diagnostic Imaging Services Market- Demand for diagnostic imaging services reached a valuation of US$ 555 Million in 2021, and is projected to reach US$ 585 Million in 2022, exhibiting a Y-o-Y growth rate of 5.4%. From 2022 to 2032, the industry is poised to grow at a CAGR of 5.51% to reach a valuation of US$ 1 Billion.
Drug Delivery Systems Market- The worldwide drug delivery systems market was worth around US$ 40 Billion in 2022 and is expected to grow at a CAGR of more than 7.8% from 2022 to 2032, reaching roughly US$ 80 Billion by 2032.
Medical Waste Management Market- The global medical waste management market, which projects market growth at a CAGR of 6.2% from 2021 to 2028. Revenue from medical waste management services accounted for US$ 15.3 Bn in 2020, and is estimated to surge to US$ 25.2 Bn by the end of 2028.
Heart Attack Diagnostics Market- The heart attack diagnostics market is predicted to grow at a moderate CAGR of 7.1% during the forecast period of 2022 to 2032. The global heart attack diagnostics market is estimated to reach a value of nearly US$ 22.2 Billion by 2032 by growing from US$ 10.4 Billion in 2021.
Drug Discovery Services Market- The drug discovery services market is forecasted to reach US$ 50 Billion by 2032, up from US$ 19 Billion in 2022, at a CAGR of 10.1%. A Y-o-Y growth rate of nearly 12% is expected for the market in 2022. As of 2021, the market was valued at US$ 17 Billion.
Lab Automation Market- Demand for lab automation services experienced a Y-o-Y expansion rate of over 11% in 2022 compared to 2021, rising from US$ 1.8 Billion to US$ 2 Billion. Going forward, the market is poised to flourish at a 7% value CAGR from 2022-2032, reaching a valuation of nearly US$ 4 Billion.
Patient Engagement Solutions Market- The global patient engagement solutions market, the market is gaining traction steadily, rising at an 8.6% CAGR through 2032, exceeding a valuation of around US$ 29 Billion by 2022. As of the end of 2032, the market is expected to reach US$ 66.4 Billion.
Smart Implants Market- The global smart implants market is estimated at US$ 3.9 billion in 2022, and is forecast to surpass a market value of US$ 22.2 billion by 2032. Smart implants are expected to contribute significantly to the global implants market, with demand surging at a CAGR of 19% from 2022 to 2032.
Facial Implants Market- The global facial implant market was valued at US$ 2.7 Billion in 2022, and is expected to rise at a 7.7% value CAGR, likely to reach US$ 5.6 Billion by the end of the 2022-2032 forecast period.
About Us:
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
Mahendra Singh
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
Email: sales@factmr.com
Tel: +1 (628) 251-1583